Sanofi: Positive results of sarilumab in efficacy, question on the safety

BUY, Fair Value EUR84.5 (+8%)

News published on November Friday 22, 2013
Share on

Sanofi is delivering positive phase III results in efficacy for sarilumab, an anti-IL6 receptor fully-human antibody, developed together with Regeneron in RA (rheumatoid arthritis). Sarilumab is actually very similar to tocilizumab, a drug marketed by the Roche Group under the brand name Actemra.


Full report available to subscribers
Please contact marketing@bryangarnier.fr   



The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities